Our medical experts have developed this in-depth overview of maribavir as a treatment option for refractory cytomegalovirus (CMV) infections in adult patients following hematopoietic stem cell transplantation (HSCT). The resource explores maribavir’s mode of action, clinical trial outcomes, resistance profiles, and real-world evidence from France, underscoring its superior efficacy in achieving CMV clearance and symptom control compared to investigator-assigned therapies. Additionally, it highlights the significant unmet needs in managing refractory CMV and offers a thorough analysis of maribavir’s safety profile.
C-ANPROM/BE/LIV/0014 July 2025